Baxfendy (Baxdrostat) Gains FDA Approval as First-in-Class Aldosterone Synthase Inhibitor for Hypertension

Baxfendy (baxdrostat) has been approved by the FDA as the first and only aldosterone synthase inhibitor for adults with uncontrolled or resistant hypertension. The BaxHTN Phase III trial showed significant blood pressure reduction and a favorable safety profile, offering a new avenue for hypertensiv

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.